Tissue markers may predict treatment response to antitumor necrosis factor‐α agents in children with Crohn's disease
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Alexander Krauthammer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schneider Children's Medical Center of Israel, Institute of Gastroenterology, Nutrition and Liver Diseases, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Crohn Disease, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Israeli Society of Pediatric Gastroenterology and Nutrition (ISPGHAN).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Patients with moderate‐severe Crohn's disease (CD) who are treated with antitumor necrosis factor alpha (TNF‐α) agents may be subjected to primary nonresponse or partial response. We aimed to identify tissue markers that may predict response to these agents.
Methods
Pediatric patients (6–18 years) with either ileal or ileo‐colonic CD who were treated with anti‐TNF‐α were stratified into three different groups based on their overall response to therapy at the end of induction including clinical and laboratory parameters (group 1—full responders [FR], group 2—partial responders [PR], group 3—nonresponders [NR]). Seven tissue markers (fibronectin, interleukin [IL]‐23R, IL‐23, TNF‐α, collagen‐III, IL‐13R, and hypoxia‐inducible factors [HIF]‐1α) were evaluated. Immunofluorescence (IF) analyses were performed on biopsies from the terminal ileum, which were retrieved up to 6 months before treatment initiation.
Results
Twenty‐six CD patients (16 [61.5%] males; age 13.9 ± 2.9 years), including 8 (30.8%) with ileal disease and 18 (69.2%) with ileo‐colonic disease, were enrolled. Terminal ileum biopsies from nine patients from group 1, nine from group 2, and eight from group 3 were evaluated. Three antibodies were found to be significantly different between NR and FR groups; Collagen III and fibronectin stains were significantly more prominent in NR patients, while TNF‐α stain was significantly more pronounced in FR, p < 0.05 for each. PR could not have been predicted with neither of markers.
Conclusions
Decreased tissue IF intensity of fibronectin and collagen III and increased intensity of TNF‐α may predict response to anti‐TNF‐α treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Schneider Children's Medical Center of Israel, Institute of Gastroenterology, Nutrition and Liver Diseases, Petah Tikva, Israel.
- Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- Felsenstein Medical Research Center, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
ORCID-Profile: Alexander Krauthammer
Förderung
- Israeli Society of Pediatric Gastroenterology and Nutrition (ISPGHAN)
Zitieren
APA
Krauthammer, A., Cozacov, T., Fried, S., Har-Zahav, A., Shamir, R., Assa, A., & Waisbourd-Zinman, O. (2024). Tissue markers may predict treatment response to antitumor necrosis factor‐α agents in children with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12146
Vancouver
Krauthammer A, Cozacov T, Fried S, Har-Zahav A, Shamir R, Assa A, et al. Tissue markers may predict treatment response to antitumor necrosis factor‐α agents in children with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12146
BibTeX
@article{Krauthammer2024,
author = {Krauthammer, Alexander and Cozacov, Tal and Fried, Sophia and Har-Zahav, Adi and Shamir, Raanan and Assa, Amit and Waisbourd-Zinman, Orith},
title = {Tissue markers may predict treatment response to antitumor necrosis factor‐α agents in children with Crohn's disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12146}
}
EUVIMED